950201-66-8

Upstream product

• 138500-88-6 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine 
• 107-82-4 i-pentyl bromide 
• 21642-98-8 4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 950201-35-1 1-Isopentyl-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 950201-36-2 1-isopentyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 330794-35-9 tert-butyl N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]carbamate 
• 950201-37-3 4-bromo-1-isopentyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 

Downstream Products

• 950201-67-9 C₃₀H₃₄FN₃O₃ 

Relevant academic research and scientific papers

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS

The present invention relates to novel compounds, in particular novel pyridinone de- rivat ives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds accord- ing to the invention are positive allosteric mod